Supervised by (2008)
Citations
1551 | Cluster analysis and display of genomewide expression patterns - MB, PT, et al. - 1486 |
662 | Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells - Al-Hajj |
574 | A genetic model for colorectal tumorigenesis. Cell - ER, Vogelstein - 1990 |
366 | Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006 - GA |
200 | Baylin SB: Gene silencing in cancer in association with promoter hypermethylation - JG - 2003 |
184 | A census of human cancer genes. Nat Rev Cancer. - PA, Coin, et al. - 2004 |
155 | Functional diversity of helper T lymphocytes. Nature - AK, KM, et al. - 1996 |
131 | Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR - TR, DK, et al. |
109 | multipotency, and the existence of two cell populations within an epithelial stem cell niche. - Blanpain, Lowry, et al. - 2004 |
85 | Sallusto F: Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol - EV, Napolitani, et al. - 2007 |
84 | Tumour stem cells and drug resistance. Nat Rev Cancer - DEAN, FOJO, et al. - 2005 |
84 | The hallmarks of cancer. Cell 100 - Hanahan, Weinberg - 2000 |
79 |
An interleukin-4-induced transcription factor:
- Hou, Schindler, et al.
- 1994
(Show Context)
Citation Context ...jor cytokine leading to the Th2 phenotype of the unpolarized Th cells. IL-4 actssthrough STAT6, and results in the Th2 phenotype and production of cytokines IL-4,sIL-13, IL-5, IL-9, IL-6, and IL-10. (=-=Hou et al., 1994-=-; Schindler et al., 1994; Seder andsPaul 1994) All the factors that contribute to the T helper cell differentiation are notsyet fully known, and the process is complex and several factors are known to... |
78 | Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 - Bettelli, Carrier, et al. |
73 | The murine gene p27Kip1 is haploinsufficient for tumour suppression. - ML, Randel, et al. - 1998 |
47 | Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116. - SB, JE - 2006 |
43 | The nuclear pore complex: nucleocytoplasmic transport and beyond - Fahrenkrog, Aebi |
40 | The two faces of - Diehl, Rincon - 2002 |
32 | Fox JG, Goldenring JR and Wang TC: Gastric cancer originating from bone marrow-derived cells. Science 306: 15681571 - JM, Stoicov, et al. - 2004 |
31 | Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol - LE, PR, et al. - 2006 |
22 | von Freeden-Jeffry U, Murray R, Weissman IL: Bcl-2 recsues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89:1033 - Akashi, Konda - 1997 |
21 |
Minimal sizes of deletions detected by comparative genomic hybridization, Genes Chromos.
- Bentz, Plesch, et al.
- 1998
(Show Context)
Citation Context ...ions of the whole genome in a single experiment.sThe main disadvantage of the technology is its limited resolution being 10-20 Mbsfor deletions and 1 Mb for amplifi cations (Kallioniemi et al., 1994; =-=Bentz et al., 1998-=-,sForozan et al., 1997). The sensitivity for deletions can be improved to 3 Mb by using standard reference intervals, based on a series of normal samples (Kirchoff et al.,s1999). The length of amplifi... |
20 | Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 5 - Bjerkvig - 2005 |
17 | Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile - Barbarotto |
17 |
Kallioniemi A, Kallioniemi OP. Genome screening by comparative genomic hybridization. Trends in Cell Biology 13
- Forozan, Karhu, et al.
- 1997
(Show Context)
Citation Context ...nome in a single experiment.sThe main disadvantage of the technology is its limited resolution being 10-20 Mbsfor deletions and 1 Mb for amplifi cations (Kallioniemi et al., 1994; Bentz et al., 1998,s=-=Forozan et al., 1997-=-). The sensitivity for deletions can be improved to 3 Mb by using standard reference intervals, based on a series of normal samples (Kirchoff et al.,s1999). The length of amplifi ed sequences that can... |
15 | Formation and detection of RNA-DNA hybrid molecules in cytological preparations - JG, ML - 1969 |
13 | Devesa SS, Fraumeni JF Jr. Hodgkin’s and non-Hodgkin’s lymphomas. Cancer Surv 1994;19-20:423-53 - Hartge |
12 | Regulatory T cells - Beissert, Schwarz, et al. - 2006 |
12 |
JD, Gazdar AF, Lam S, MacAulay C, Lam WL: High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH
- Garnis, WW, et al.
(Show Context)
Citation Context ...s of 13q,s17p, and 19, as well as 18 gain, which were present in fewer samples. The changesscommon to both CTCL and lung cancer were loss of 10q, 13q and 17p, and gains ofs7 and 8q (Coe et al., 2006; =-=Garnis et al., 2006-=-). Additionally, in CTCL-associated lungs46 cancer, some aberrations frequent in primary / reference lung cancer, were rare, if anys(detected in maximum one of the fi ve cases), especially 4q loss, 8p... |
11 | Cleton-Jansen AM, Cornelisse CJ . Ever since Knudson. Trends Genet 17: 569573 - Devilee - 2001 |
10 | Echchakir H, Mami-Chouaib F, Delfau-Larue MH, Charue D, Bernheim A, Chouaib S, Boumsell L, Bensussan A: solation of TumorSpecific Cytotoxic CD4+ and CD4+CD8dim+ T-Cell Clones Infiltrating a Cutaneous T-Cell Lymphoma. Blood - Bagot - 1998 |
10 | Molecular themes in oncogenesis - JM - 1991 |
10 |
RB, Aaltonen LA, de la Chapelle A. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 56
- Canzian, Salovaara, et al.
- 1996
(Show Context)
Citation Context ...d decreased 40% or more compared to its matching normal and decrease ofs21–39% of one allele relative to the other allele (in tumor tissue compared to matching normal tissue) is termed putative LOH. (=-=Canzian et al., 1996-=-). Table 6. Microsatellite markers used for NAV3 LOH analysis Marker Distance from NAV3 1) 5' - F primer - 3' 2) 5' - R primer - 3' D12S1684 1.0 Mb 1) CCTGCATGCCTCAGTTATGA 2) AACAAGCCATACCAGTCAGG D12S... |
10 |
H: Clinicopathologic and immunologic features associated with transformation od mycosis fungoides to large cell lymphoma. Am J surg Pathol 16:543
- Cerroni, Rieger, et al.
- 1992
(Show Context)
Citation Context ...l course and the disease progresses slowly. The estimated 5-year survival is 88% (Willemze et al., 2005). In advanced stages progression tosa CD30+ or CD30- large cell T-cell lymphoma may be present (=-=Cerroni et al., 1992-=-).sThe treatment is based on the stage (IA-IVB) of the disease. Aggressive therapy doessnot improve the prognosis or remission time. Skin-directed therapy usually leads tosremissions in the early stag... |
10 | Sekido Y, Gazdar AF and Minna JD. Lung cancer 9: Molecular biology of lung cancer: clinical implications. Thorax 2003; 58: 892–900 - KM |
9 |
Tickenbrock L, Lang K, Zänker KS, Metzger R, Schneider PM
- Diederichs, Bulk, et al.
- 2004
(Show Context)
Citation Context ... observed in both SS and MF PBMCssamples. S100P has a role in cell cycle progression and differentiation, and its upregulation has been found in various malignancies (Guerreiro Da Silva et al., 2000;s=-=Diederichs et al., 2004-=-; Sato et al., 2004; Hammacher et al., 2005). Because an expression bias for S100P was found in mycosis fungoides blood samples also, S100Psmay have a role in the early oncogenesis of CTCL. In additio... |
9 |
Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer
- Hammacher, Thompson, et al.
- 2005
(Show Context)
Citation Context ...00P has a role in cell cycle progression and differentiation, and its upregulation has been found in various malignancies (Guerreiro Da Silva et al., 2000;sDiederichs et al., 2004; Sato et al., 2004; =-=Hammacher et al., 2005-=-). Because an expression bias for S100P was found in mycosis fungoides blood samples also, S100Psmay have a role in the early oncogenesis of CTCL. In addition, membrane-boundsLIR9 (215838_at) was over... |
8 | Chromosomal imbalances in human lung cancer. Oncogene 21 - BR, JR - 2002 |
8 |
Santarlasci V, Manetti R, Lasagni L, Vanini V, Romagnani P, Maggi E et al. (2004) Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines
- Cosmi, Liotta, et al.
(Show Context)
Citation Context ...gression to the leukaemic phase. This kind of a skewing is likely tosinfl uence the progressive immune dysregulation in CTCL and would thus provide asgrowth advantage for the malignant cell clone(s) (=-=Cosmi et al., 2004-=-). 5.2.3 Histogenesis of SPTL This study clarifi ed the classifi cation of cutaneous T-cell lymphomas. When the studyswas begun, subcutaneous panniculitis-like T-cell lymphomas were classifi ed amongs... |
8 | Poustka A. Pore membrane and/or fi lament interacting like protein 1 (POMFIL1) is predominantly expressed in the nervous system and encodes different protein isoforms. Gene - JF, Wiemann, et al. - 2002 |
8 | Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma - Ferenczi |
7 |
Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity
- Cella, Fujikawa, et al.
- 2004
(Show Context)
Citation Context ... is known to augment antitumor responsess(Cairns et al., 2001), and VAV3, like the other two VAV proteins, functions specifi callysin signaling pathways that trigger natural killer cell cytotoxicity (=-=Cella et al., 2004-=-).sKIR3DL2 (CD158K), a member of the killer cell immunoglobulin-like receptors, hassbeen suggested previously as a phenotypic marker for Sezary cells (PoszepczynskaGuigne et al., 2004) and has been fo... |
7 | Bagot M, Mossalayi MD, Fourcade C, Thacker DJ - Dalloul, Laroche - 1992 |
6 | LIR9, an immunoglobulin-superfamily-activating receptor, is expressed as a transmembrane and as a secreted molecule - Borges, Kubin, et al. |
6 |
IL-15 is an autocrine/paracrine viability factor for cutaneous T cell lymphoma cells
- Döbbeling, Dummer, et al.
- 1998
(Show Context)
Citation Context ...eration insthe skin. Autocrine IL-2, keratinocyte-derived IL-7, and APC-derived IL-15 are thesmost important growth factors promoting growth and survival of CTCL cells in vitros(Dalloul et al., 1992; =-=Döbbeling et al., 1998-=-). In later stages of CTCL, tumor cells maysbecome independent of these exogenous signals, e.g. by autocrine production of IL15 or by interactions via STAT (signal transducers and activators of transc... |
6 |
Alternatively spliced forms of human killer inhibitory receptors. Immunogenetics
- Dohring, Samaridis, et al.
- 1996
(Show Context)
Citation Context ...4). Contradictory, in this study the KIR3DL2 gene was downregulated insSezary syndrome samples. The discrepant observations of KIR3DL2 may be due tosthe considerable polymorphism of the KIR3DL2 gene (=-=Dohring et al., 1996-=-; Gardinerset al., 2001), or may refl ect the fact that only about half of the expanded T-cell clonessexpress CD158K and that CD158K expression is heterogeneous even within the malignant clones (Orton... |
6 |
G: Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-g receptor b-chain). Blood 88:1383
- Dummer, PW, et al.
- 1996
(Show Context)
Citation Context ...ss of CD7 and CD26 (Vonderheid etsal., 2002; Willemze et al., 2005). The tumor cells are usually CD3+, CD4+, CD8-,sCD45RO+, CD30-, and mature Th2 memory cells (Vowels et al., 1992, Saed et al.,s1994; =-=Dummer et al., 1996-=-; Willemze et al., 2005). The prognosis in SS is poor, 5-yearssurvival being only 24% (Table 1). No curative therapy exists, but therapy recommendations include extracorporeal photopheresis either alo... |
6 | ZC: Characterization and neural differentiation of fetal lung mesenchymal stem cells. Cell Transplant - CG, FW, et al. - 2005 |
5 | Edelson RL. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells - CL, Tigelaar, et al. |
5 | Baca-Estrada ME, Moyana T, Xiang J. Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor - CM, JR, et al. - 2001 |
5 | Vonderheid EC, Kadin ME. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin - Dereure, Levi |
5 | Guilhou JJ. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4 T lymphocytes in cutaneous T-cell lymphomas - Dereure, Portales, et al. |
5 |
Frankel AE. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma
- Duvic, Cather, et al.
- 1998
(Show Context)
Citation Context ...affi nity IL-2R is expressed on ca. 50% of CTCL cells (Jones et al., 2004). Consequently, IL-2-targeted therapy has beensused for CTCL, most recently with a fusion protein denileukin diftitox (ONTAK; =-=Duvic et al., 1998-=-). Interestingly, the retinoid X receptor retinoid, bexarotene, a new therapeutic agent for mycosis fungoides (Duvic et al., 2000), upregulates both the α andsβ subunits of IL-2R. This, in turn, enhan... |
5 | Demierre MF, DiVenuti G. A phase 1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106: 454457 - Foss - 2005 |
5 |
The pathogenesis of mycosis fungoides
- Girardi, PW, et al.
- 2004
(Show Context)
Citation Context ...ne rearrangement analysis in unspecifi cs(Lukowsky et al., 2000; Sawabe et al., 2000) Further staging of MF is achieved by criteria proposed by North American MFsCooperative Group (Bunn et al., 1979; =-=Girardi et al., 2004-=-) recently revised by the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphomastask force of the EORTC (Olsen et al., 2007). MF is divided into four stages based onsskin, no... |
5 | Serological immunomarkers in cutaneous T cell lymphoma. Dermatology - JC, Meier, et al. |
5 | Loyaux D, Capdevielle J, Conraux L, Ferrara P, Bensussan A, et al., SC5 mAb represents a unique tool for the detection of extracellular vimentin as a specific marker of Sezary cells - Huet, Bagot |
4 | C-KIT expression in primary cutaneous T-cell lymphomas - TC, Schultewolter, et al. |
4 | Giri AA, Banks L, Gardiol D. Differential expression of the human homologue of drosophila discs large oncosuppressor in histologic samples from human papillomavirus-associated lesions as a marker for progression to malignancy - AL, Fumero, et al. - 2004 |
4 | JD, Gazdar AF, Lam S, MacAulay C, Lam WL. Gain of a region on 7p22.3, containing MAD1L1, is the most frequent event in small-cell lung cancer cell lines. Genes Chromosomes Cancer - BP, EH, et al. - 2006 |
4 |
Therapy of cutaneous lymphoma--current practice and future developments. Onkologie 26
- Dummer, Kempf, et al.
- 2003
(Show Context)
Citation Context ...patientsswill suffer from a relapse. MF confi ned to skin is treated with photo(chemo)therapy:sUVB irradiation and PUVA, whereas combination chemotherapy is recommendedsfor systemic CTCL (stage IV). (=-=Dummer et al., 2003-=-; Whittaker et al., 2003; Trautingerset al., 2006)s1.2.1.2 Sezary syndrome (SS) Sezary syndrome (SS) is the leukaemic form of CTCL, where malignant T lymphocytesscirculate in the blood (Sezary et al.,... |
4 | A gene hypermethylation profi le of human cancer - Esteller, PG, et al. - 2001 |
4 |
Estrach T, Servitje O. Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas. Haematologica
- Gallardo, Esteller, et al.
- 2004
(Show Context)
Citation Context ...et al., 2004), the epigenetic gene silencing is speculated tosbe important in CTCL. In CTCL, promoter hypermethylation of genes encoding CDKN2A (Navas et al., 2000 and 2002; Scarisbrick et al., 2002, =-=Gallardo et al., 2004-=-), CDKN2B (Scarisbrick et al., 2002; Gallardo et al., 2004), MLH1 (Scarisbrick et al., 2003),sMGMT (Gallardo et al., 2004); BCL7A, PTPRG, TP73, and THBS4 (van Doorn et al.,s2005) has been reported, an... |
4 |
Tumour suppression: putting on the brakes. Nature 427
- Harris
- 2004
(Show Context)
Citation Context ...ls forming the primary tumor,snamely the cancer stem cells, which apart from being capable of self-renewal andsproliferation, also contribute to drug resistance and express typical stem cell markers (=-=Harris, 2004-=-; Dean et al., 2005; Polyak and Hahn, 2006). Cancer stem cells aresresponsible for initiating and sustaining tumor growth but are predicted to be refractory to current therapies which are designed to ... |
4 |
T-cell clones from early-stage cutaneous T-cell lymphoma show no polarized Th-1 or Th-2 cytokine profi le. Arch Dermatol Res 292
- Harwix, Zachmann, et al.
- 2000
(Show Context)
Citation Context ... profi le of SS was confi rmed, but reports on MF showedsnonconsistent fi ndings with cytokine profi le favouring Th1 or Th2 polarization or nospolarization (Vowels et al., 1994; Dummer et al., 1996; =-=Harwix et al., 2000-=-). Besidesscytokine profi ling, also transcription factor level characteristics of CTCL have beensrevealed. Overexpression of GATA-3 and underexpression of STAT4 have been reported in Sezary syndrome ... |
3 | Description des maladies de la peau observées à l’Hôpital Saint-Louis et exposion des meilleures méthodes suivies pour leur traitement. Paris, Barrois l’aîné et fi ls - Alibert |
3 | Rev Drug Discov 5 - Nat - 2006 |
3 |
Difl o T, Glusac E, Hyman K, Theise ND, Krause DS. Bone marrow-derived cells contribute to epithelial engraftment during wound healing
- Borue, Lee, et al.
- 2004
(Show Context)
Citation Context ...entsde-differentation. Still another possibility is that bone marrow –derived CD34+ stemscells migrate to sites of tissue damage, where they become tissue-specifi c stem cellss(Passegue et al., 2003; =-=Borue et al., 2004-=-; Bjerkvig et al., 2005; Polyak and Hahn, 2006).sThere is experimental evidence supporting all these pathways, and it may be, that insdifferent tumour types, different pathways operate (Polyak and Hah... |
3 | Report of the Committee on Staging and Classifi cation of Cutaenous T-cell lymphomas. Cancer Treatment Reports - PA, SI - 1979 |
3 | Gazdar AF. Small cell lung cancer, endocrine cells of the fetal bronchus, and other neuroendocrine cells express the Leu-7 antigenic de- terminant present on natural killer cells - PA, Linnoila, et al. |
3 | Tellingen O, Berns A. Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol - Calbo, Meuwissen, et al. - 2005 |
3 | Fearneyhough PK, Callen JP. Subcutaneous panniculitis-like T-cell lymphoma with vacuolar interface dermatitis resembling lupus erythematosus panniculitis - TB - 2004 |
3 | Clin Invest 88 - unknown authors - 1991 |
3 | Rajalingam R, Vilches C, Parham P. Different NK cell surface phenotypes defi ned by the DX9 antibody are due to KIR3DL1 gene polymorphism - CM, LA, et al. - 2001 |
3 |
Neoplastic stem cells in cutaneous lymphomas: evidence and clinical implications. Arch Dermatol 140
- Gniadecki
- 2004
(Show Context)
Citation Context ...so far, although there are preliminarysreports of the initial malignant transformation to occur in bone marrow in a lowgrade cutaneous lymphoma, namely lymphomatoid papulosis (Gniadecki et al., 2003;s=-=Gniadecki, 2004-=-). It has been speculated that bone marrow –derived stem cells wouldsmigrate to the site of chronic skin infl ammation (like Parapsoriasis en plaques), oftenspreceding CTCL, and then either fuse with ... |
3 | The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 157 - Gniadecki, Assaf, et al. - 2007 |
3 | T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome - CL, LJ, et al. - 1991 |
2 |
Hansen-Hagge TE, Döcke WD, Volk H-D, Sterry W. IL-15 and IL-16 overexpression in cutaneous T cell lymphomas: stage dependent increase in mycosis fungoides progression. Exp Dermatol 9: 248251
- Asadullah, Haeußler-Quade, et al.
- 2000
(Show Context)
Citation Context ...f CTCL, tumor cells maysbecome independent of these exogenous signals, e.g. by autocrine production of IL15 or by interactions via STAT (signal transducers and activators of transcription)smolecules (=-=Asadullah et al., 2000-=-; Qin et al., 1999, 2001). Disturbances in STAT signalling pathways have been observed in CTCL, e.g. constitutive STAT3 activation (Zhangset al., 1996), loss of STAT1 and STAT4 protein expression (Tra... |
2 | Sivori S, Biassoni R, Cantoni C, Bottino C, Boumsell L, Bensussan A. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 97 - Bagot, Moretta - 2001 |
2 |
Griffi n CA. Multicolor fl uorescence in situ hybridization (SKY) in mycosis fungoides and Sézary syndrome: Search for recurrent chromosome abnormalities. Genes Chromosomes Cancer 45
- Batista, EC, et al.
- 2006
(Show Context)
Citation Context ... 12 (4/9), in which the majority of the abnormalities were structural (Batista etsal., 2006). Moreover, recurrent breakpoints were observed in 1p32-p36, 6q22-q25,s17p11.2-p13, 10q23-q26, and 19p13.3 (=-=Batista et al., 2006-=-), regions often showingsDNA copy number losses in CGH studies (see 1.2.2.2; Karenko et al., 1999; Mao et al.,s2002; Fischer et al., 2004).sCross-species colour banding (Rx-FISH, Müller et al., 1997, ... |
2 |
Affections cutanées artifi cielles
- Bazin
- 1852
(Show Context)
Citation Context ...illemze et al., 2005).s17 Clinically MF presents classically with the evolution of skin lesions from patches tosplaques and tumors mainly affecting trunk and other sun-protected areas (Alibert,s1806; =-=Bazin, 1852-=-; Figure 1A). The diagnosis of MF is diffi cult, since it often resembles eczema or mild psoriasis in its earliest stages. Often long-lasting observation ofsthe clinical picture together with multiple... |
2 | FR. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 12: 3652–3656 - Jr, Dziadziuszko, et al. - 2006 |
2 | Kadin M: From infl amation to neoplasia. Mycosis fungoides evolves from reactive infl ammatory conditions (lymphoid infi ltrates) transforming into neoplastic plaques and tumors. Arch Dermatol 137: 949952 - Burg, Dummer, et al. - 2001 |
2 | Hedgcock CJ, Wong HK. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 14 - BF, AJ, et al. - 2008 |
2 | García-Sanz R, González M, Sánchez-García I. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 95 - Cobaleda, Gutiérrez-Cianca, et al. - 2000 |
2 | Accommodating haploinsuffi cient tumor suppressor genes in Knudson’s model. Oncogene 19 - WD, BJ - 2000 |
2 | Furge KA. Identifi cation of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol 3: RESEARCH0075 - JJ - 2002 |
2 | Bigoni R, Roberti MG, Bardi A, Balsamo R, Piva N, Castoldi G. Detection of numerical aberrations in hematologic neoplasias by fl uorescence in situ hybridization. Haematologica 82 - Cuneo - 1997 |
2 | AK, Breuning MH, van Ommen GJB. Multiple colors by fl uorescence in situ hybridization using ratio-labelled DNA probes create a molecular karyotype. Hum Mol Genet 1 - JG, Wiegant, et al. - 1992 |
2 |
Degos L, Boumsell L, Bensussan A. Identifi cation of a novel 110-kilodalton structure expressed on a subset of T cell receptor-gamma delta-bearing cloned lymphocytes
- David, Bachelez, et al.
- 1990
(Show Context)
Citation Context ...mab), IL2R (Ontak), or CD4 molecules (zanolimumab). The usage of antibodybased therapy requires the malignant cells to express the certain membrane antigen.sMonoclonal antibodies are easy to prepare (=-=David et al., 1990-=-; Nikolova et al., 2001),sand thus suitable therapy means targeted against membrane proteins. In the genesexpression analysis (Study II), upregulated genes included MS4A4A and LIR9, whichswould become... |
2 | Bexarotene and DAB(389)IL2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clin Lymphoma 1 - Duvic - 2000 |
2 |
Servitje O, Estrach T, Garcìa-Muret P, Woessner S, Serrano S, Solé F. Genetic characterization of Sézary’s syndrome by conventional cytogenetics and cross-species color banding fl uorescent in situhybridization. Haematologica
- Espinet, Salido, et al.
- 2004
(Show Context)
Citation Context ...rming bands. Espinet and coworkers used this technology in addition to thesconventional cytogenetics, and revealed aberrations in chromosomes 10, 1, 6, 8, 9, 11,sand 17 to be frequent in SS patients (=-=Espinet et al., 2004-=-). Still another novel technology, COBRA-FISH (Tanke et al., 1999), which is basedson the simultaneous use of combinatorial (binary) labelling and ratio labelling, hassrecently been used in CTCL resea... |
2 | Profi ling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109 - Esteller - 2003 |
2 | Rev Genet 7 - Nat - 2006 |
2 | Muche JM, Sherev T, Audring H, Neitzel H, Walden P, Sterry W, Tönnies H. Genomic aberrations and survival in cutaneous T cell lymphomas - TC, Gellrich - 2004 |
2 | Sausville EA. Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin2: potential autocrine or paracrine effectors in the Sézary syndrome - FM, Koc, et al. - 1994 |
2 | Contassot E, Arrighi JF, Piguet V, Calderara S, Rook AH. Impaired CD40L signaling is a cause of defective IL12 and TNFá production in Sezary syndrome: circumvention by hexameric soluble CD40L. Blood 105 - LE, Huard, et al. - 2005 |
2 | and genomics. Nature 409 - Cancer - 2001 |
2 | marrow precursor of extranodal T-cell lymphoma - Bone - 2003 |
2 | DH. Detection of specifi c polymerase chain reaction product by utilizing the 5’----3’ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88 - PM, RD, et al. - 1991 |